Blood pressure variability after intravenous thrombolysis in acute stroke does not predict intracerebral hemorrhage but poor outcome

Cerebrovascular Diseases

Volumn 33, Issue 2, 2012, Pages 135-140

  Kellert, Lars ^a   Sykora, Marek ^a,b   Gumbinger, Christoph ^a   Herrmann, Oliver ^a   Ringleb, Peter A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Physics and Informatics   (Slovakia)

Author keywords

Acute stroke; Blood pressure variability; Intracerebral hemorrhage; Intravenous thrombolysis; Stroke

Indexed keywords

ALTEPLASE;

ACUTE DISEASE; AGE; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD PRESSURE VARIABILITY; BRAIN HEMORRHAGE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIASTOLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STROKE; SYSTOLE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CEREBRAL HEMORRHAGE; DISABILITY EVALUATION; FEMALE; FIBRINOLYTIC AGENTS; GERMANY; HUMANS; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 83455258215     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000334186     Document Type: Article

References (15)

1. Larrue V, von Kummer R, Mller A, Bluhmki E: Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32: 438-441. (Pubitemid 32155231)
2. The National Institute of Neurological Disorders and Stroke rt-PA Study Group: Tissue plasminogen activator. N Engl J Med 1995; 333: 1581-1587.
3. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxzer G, Mahagne MH, Hennerici M: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
4. Tanne D, Kasner SE, Demchuk AM, Koren- Morag N, Hanson S, Ground M, Levine SR: Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the multicenter rt-PA Stroke Survey. Circulation 2002; 105: 1679-1685. (Pubitemid 34298612)
5. Demchuk AM, Morgenstern LB, Krieger DW, Linda Chi T, Hu W, Wein TH, Hardy RJ, Grotta JC, Buchan AM: Serum glucose level and diabetes predict tissue plasminogen activator- related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999; 30: 34-39. (Pubitemid 29029438)
6. Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators: Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172: 1307-1312. (Pubitemid 40745072)
7. Gilligan AK, Markus R, Read S, Srikanth V, Hirano T, Fitt G, Arends M, Chambers BR, Davis SM, Donnan GA, Australian Streptokinase Trial Investigators: Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke 2002; 33: 2236-2242. (Pubitemid 35014636)
8. Rothwell PM, Howard SC, Dolan E, O'Brian E, Dobson JE, Dahlöf B, Sever PS, Poulter NR: Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.
9. Yong M, Diener HC, Kaste M, Mau J: Characteristics of blood pressure profiles as predictors of long-term outcome after acute ischemic stroke. Stroke 2005; 36: 2619-2625.
10. Yong M, Kaste M: Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial. Stroke 2008; 39: 366-372. (Pubitemid 351619457)
11. Delgado-Mederos R, Ribo M, Rubiera M, Munuera J, Santamarina E, Delgado P, Maisterra O, Alvarez-Sabin J, Molina CA: Prognostic significance of blood pressure variability after thrombolysis in acute stroke. Neurology 2008; 71: 552-558.
12. Ko Y, Park JH, Yang MH, Ko SB, Han MK, Oh CW, Lee J, Lee J, Bae HJ: The significance of blood pressure variability for the development of hemorrhagic transformation in acute ischemic stroke. Stroke 2010; 41: 2512-2518.
13. Geeganage C, Tracy M, England T, Sare G, Moulin T, Woimant F, Christensen H, De Deyn PP, Leys D, O'Neill D, Ringelstein EB, Bath PM, for TAIST Investigators: Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure, and variability) and early outcome after stroke: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). Stroke 2011; 42: 491-493.
14. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European- Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251. (Pubitemid 28470336)
15. Molina CA, Alvarez-Sabin J, Montaner J, Abilleira S, Arenillas JF, Coscojuela P, Romero F, Codina A: Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002; 33: 1446-1447.